Aspire Biopharma Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aspire Biopharma Holdings, Inc. (ASBP) on September 22, 2025. The company is an emerging growth company incorporated in Delaware with principal executive offices in Estero, Florida. The filing discloses two material events: the receipt of a second tranche of funding under a Securities Purchase Agreement and a change in the company's independent registered public accounting firm.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data for the period. However, it discloses specific capital raising activity:
- Total Note Principal: $9,687,500
- Total Subscription Price: $7,750,000
- Funding Received (August 19, 2025): $4,709,677
- Funding Received (September 22, 2025): $1,000,000
- Remaining Funding: The filing does not explicitly state the status of the remaining balance of the subscription price.
Material Changes
Accounting Firm Change: On September 22, 2025, the Audit Committee dismissed Bush & Associates CPA as the independent registered public accounting firm. The firm's report for the year ended December 31, 2024, included an explanatory paragraph regarding substantial doubt as to the Company's ability to continue as a going concern. The Committee simultaneously appointed Turner Stone & Co as the new independent registered public accounting firm for the fiscal year ending December 31, 2025.
Internal Controls: The company disclosed material weaknesses in its internal control over financial reporting for the year ended December 31, 2024, and subsequent interim periods. Management concluded that disclosure controls and procedures were not effective as of December 31, 2024, though financial statements were prepared in accordance with US GAAP.
Outlook, Risks, and Contingencies
Going Concern Risk: The previous auditor's report highlighted substantial doubt regarding the company's ability to continue as a going concern. While the recent funding provides liquidity, the filing does not explicitly state that this risk has been fully mitigated.
Management Commentary: There were no disagreements with the former auditor regarding accounting principles or audit scope. The former auditor confirmed it does not disagree with the statements made in this report regarding the change.
Investor Verification Checklist
- Verify the total amount of the remaining subscription price ($7,750,000 total - $5,709,677 received) and the timeline for its receipt.
- Review the company's most recent Form 10-K or 10-Q to assess the current status of the "substantial doubt" regarding going concern.
- Confirm the specific nature of the material weaknesses in internal controls and the remediation plan implemented by management.
- Check for any subsequent filings regarding the terms of the notes issued (interest rates, maturity dates, conversion features).